QQ客服 官方微博 反馈留言

	Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE,
	Song, Yong; Wu, Yi-Long; Cao, Le-Jie; Chen, Jian-Hua; Ma, Zhi-Yong; Cui, Jiu-Wei; Wang, Jie; Liu, Hong-Bing; Ding, Jing-Yan; Hu, Min
	2019
卷号	42期号:5页码:432-439
关键词	re-challenge gefitinib T790M mutation progression-free survival EGFR-TKI NSCLC
ISSN号	0277-3732
DOI	10.1097/COC.0000000000000538
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6337085
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Song, Yong,Wu, Yi-Long,Cao, Le-Jie,et al. Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE,[J],2019,42(5):432-439.
APA	Song, Yong.,Wu, Yi-Long.,Cao, Le-Jie.,Chen, Jian-Hua.,Ma, Zhi-Yong.,...&Hu, Min.(2019).Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE,.,42(5),432-439.
MLA	Song, Yong,et al."Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE,".42.5(2019):432-439.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。